Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00955825 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis
A Phase 3 study, sponsored by Stallergenes Greer.
- Completed
- Registry status
- Phase 3
- Development phase
- 473
- Enrollment target
NCT00955825 is a Phase 3 study that has completed, run by Stallergenes Greer. The registered enrollment target is 473 participants.
The verdict
NCT00955825, a Phase 3 study, has completed, sponsored by Stallergenes Greer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 473 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy and safety of 300 IR sublingual tablet of grass pollen allergen extract compared to placebo in adult patient with allergic rhinoconjunctivitis.
Interventions
- DRUG Placebo
- DRUG 300 IR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 473 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00955825
The ClinicalTrials.gov registry entry for NCT00955825 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 473 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stallergenes Greer, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00955825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00955825 about?
NCT00955825 is a clinical study titled "Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis". The purpose of the study is to assess the efficacy and safety of 300 IR sublingual tablet of grass pollen allergen extract compared to placebo in adult patient with allergic rhinoconjunctivitis.
What is the current status of trial NCT00955825?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 473 participants. The study started on 2008-10. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00955825?
The interventions under investigation include: Placebo (DRUG), 300 IR (DRUG).
Who is sponsoring clinical trial NCT00955825?
This trial is sponsored by Stallergenes Greer, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.